<DOC>
	<DOCNO>NCT02249078</DOCNO>
	<brief_summary>This multicenter , Phase 1b , randomize , double-blind , placebo-controlled , sequential-cohort , multiple ascend dose ( MAD ) study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) 3 subcutaneous 1 intravenous dose E6011 subject active Crohn 's disease ( CD ) . Thirty-two subject randomize one 4 dose cohort ( 8 per cohort ) receive E6011 placebo 10 week . The first 3 cohort receive E6011 placebo via subcutaneous injection last cohort receive E6011 placebo intravenous injection . The ratio E6011 placebo within cohort 3:1 . The study 2 phase : Prerandomization Randomization .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics 3 Subcutaneous 1 Intravenous Dose E6011 Subjects With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Male female subject age great equal 18 year old time inform consent 2 . Confirmed diagnosis CD , least one document lesion within reach colonoscope ( terminal ileal ileocolonic colonic ) previous colonoscopy , minimum duration 6 month time screen 3 . Active CD CD activity index ( CDAI ) score great equal 220 less equal 450 4 . Colonoscopic evidence CD involvement active inflammation terminal ileum and/or colon Screening ( perform subject otherwise meet inclusion none exclusion criterion ) 5 . Inadequate response , loss response , intolerance least one follow agent define : Immunomodulators : Signs symptom persistently active disease despite history least one 8week regimen oral azathioprine ( AZA ) ( great equal 1.5 mg/kg ) 6mercaptopurine ( 6MP ) mg/kg ( great equal 0.75 mg/kg ) OR Signs symptom persistently active disease despite history least one 8week regimen methotrexate ( MTX ) ( great equal 12.5 mg/week ) History intolerance least 1 immunomodulator ( include , limited ) nausea/vomiting , abdominal pain , pancreatitis , liver function test ( LFT ) abnormality , lymphopenia , thiopurine methyltransferase ( TPMT ) genetic mutation , infection Tumor Necrosis Factor ( TNF ) alpha antagonist : Signs symptom persistently active disease despite history least one 4week induction regimen one follow agent : Infliximab : 5 mg/kg IV , 2 dos least 2 week apart Adalimumab : one 80 mg SC dose follow one 40mg dose least 2 week apart Certolizumab pegol : 400 mg SC dose , 2 dos least 2 week apart OR Recurrence symptom schedule maintenance dosing follow prior clinical benefit ( discontinuation despite clinical benefit qualify ) History intolerance least 1 TNF antagonist ( include , limited infusionrelated reaction , demyelination , congestive heart failure , infection ) 6 . Creactive protein great equal 5 mg/L screen fecal calprotectin great equal 250 ug/g 7 . Females must breastfeed pregnant Screening ( document negative betahuman chorionic gonadotropin [ BhCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 8 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 70 day study drug discontinuation . If currently abstinent , subject must agree use doublebarrier method describe becomes sexually active study period 70 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week dose must continue use contraceptive study 70 day study drug discontinuation . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 9 . Provide write informed consent 10 . Willing able comply aspect protocol Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Evidence clinically significant disease ( eg , cardiac , respiratory , gastrointestinal [ CD ] , renal disease , active infection , vasculitides ) opinion investigator ( ) could affect patient 's safety interfere study assessment 2 . Any neurologic abnormality screen 3 . A prolonged QT/QTc interval ( QTc great 450 m ) demonstrate repeat ECG Screening 4 . History severe allergy 5 . Scheduled surgery plan participation study 6 . Previous ileocolonic resection presence ostomy 7 . Presence active fistulizing CD 8 . Total parenteral nutrition ( TPN ) enema treat CD within 2 week Screening 9 . Treatment adalimumab certolizumab within 2 week Screening 10 . Treatment infliximab within 4 week ( 8 week subject receive 10 mg/kg ) Screening 11 . Treatment vedolizumab ( case approval offlabel use ) monoclonal antibody within 8 week start study treatment 12 . History treatment natalizumab 13 . Changes dose 5aminosalicylic acid , 6MP , MTX , AZA therapy within 4 week Screening 14 . Doses great 30 mg/day prednisone equivalent Screening 15 . Parenteral corticosteroid use within 4 week Screening 16 . Treatment cyclosporine ( oral IV ) , tacrolimus hydrate ( exclude eyedrop skin cream ) , sirolimus , mycophenolate mofetil within 8 week Screening 17 . Positive Clostridium difficile toxin test Screening 18 . Known human immunodeficiency virus ( HIV ) positive Screening 19 . History tuberculosis know current active tuberculosis 20 . Positive result Mycobacterium tuberculosis use InterferonGamma Release Assay Screening 21 . Active viral hepatitis ( B C ) demonstrate positive serology Screening 22 . Use live vaccine immunoglobulin preparation within 12 week screen 23 . Cluster differentiation4 ( CD4 ) positive cell count 200/microliter ( uL ) white blood cell count 3,000/uL screen 24 . Any following laboratory abnormality test conduct Screening Hemoglobin : less 8.0 g/dL Neutrophil count : le 1,500/uL Platelet count : le 100,000/uL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : great 2.5 time upper limit standard reference value Serum creatinine : great 1.5 mg/dL 25 . Psychotic disorder ( ) unstable recurrent affective disorder ( ) evident use antipsychotic prior suicide attempt ( ) within approximately last 2 year 26 . History drug alcohol dependency abuse within 2 year prior Screening 27 . Current use illegal recreational drug 28 . Currently enrol another clinical study use investigational drug device within 28 day precede informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>